Faverio, 901 patient N-acetylcysteine late treatment study: 19% higher mortality [p=0.33], 34% higher ICU admission [p=0.08], and 1% higher hospital discharge [p=0.94] https://c19p.org/faverio
copied to clipboard
Impact of N-acetyl-l-cysteine on SARS-CoV-2 pneumonia and its sequelae: results from a large cohort study
et al., ERJ Open Research, doi:10.1183/23120541.00542-2021
Retrospective 1,083 consecutive hospitalized COVID patients in Italy, showing no significant differences with NAC treatment. STORM. NCT04424992.
|
risk of death, 19.0% higher, RR 1.19, p = 0.33, treatment 91 of 572 (15.9%), control 44 of 329 (13.4%), inverse propensity weighting.
|
|
risk of ICU admission, 33.8% higher, RR 1.34, p = 0.08, treatment 107 of 572 (18.7%), control 46 of 329 (14.0%), inverse propensity weighting.
|
|
risk of no hospital discharge, 1.4% lower, RR 0.99, p = 0.94, treatment 180 of 572 (31.5%), control 105 of 329 (31.9%), NNT 224, inverse propensity weighting.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Faverio et al., 12/2/2021, retrospective, Italy, Europe, peer-reviewed, 10 authors, study period February 2020 - April 2021, trial NCT04424992.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.